A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF)
Latest Information Update: 21 Dec 2021
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms INJOURNEY
- Sponsors Boehringer Ingelheim
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 11 Sep 2017 Results published in the Boehringer Ingelheim Media Release
- 10 Sep 2017 Results published in the American Journal of Respiratory and Critical Care Medicine